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Signal transduction via G-protein coupled receptors (GPCRs) relies upon the production
of cAMP and other signaling cascades. A given receptor and agonist pair, produce
multiple effects upon cellular physiology which can be opposite in different cell types.
The production of variable cellular effects via the signaling of the same GPCR in different
cell types is a result of signal organization in space and time (compartmentation).
This organization is usually based upon the physical and chemical properties of the
membranes in which the GPCRs reside and the repertoire of downstream effectors and
co-factors that are available at that location. In this review we explore mechanisms of
GPCR signal compartmentation and broadly review the state-of-the-art methodologies
which can be utilized to study them. We provide a clear rationale for a “localized”
approach to the study of the pharmacology and physiology of GPCRs and particularly
the secondary messenger cAMP.
Keywords: GPCRs, cAMP, compartmentation, caveolae, T-tubules, lipid rafts, scanning ion conductance
microscopy, FRET sensors
Introduction
The members of the G-protein coupled receptor (GPCR) family act through multiple pathways
upon activation as they possess the ability to bind a panel of G-proteins and b-arrestins. As a
result ligand binding can potentially activate multiple effector pathways with differential effects
upon cellular physiology. The array of these effectors is vast and outside of the scope of both
this article and this review series, readers are therefore encouraged to consult previous reviews
(Neves et al., 2002; Kenakin, 2011; Shukla et al., 2011). However, in the setting of specialized
tissues and cells GPCRs are located into specific compartments with defined molecular profiles,
which strictly determine the potential physiological outcomes of signaling. The consequence is that
althoughGPCR signaling is potentially “omnidirectional,” in reality signaling outcomes are restricted
by the accessibility of secondary signaling molecules such as cyclic adenosine monophosphate
(cAMP) and cyclic guanosine monophosphate (cGMP) and the presence of their modulators such
as phosphodiesterases or protein kinases activated by the cyclic nucleotides. For a comprehensive
and exhaustive review on the cyclic nucleotides and their modulators in cardiac cells the reader is
encouraged to refer to the works of the Zaccolo andMovsesian (2007) or the Conti group (Conti and
Beavo, 2007).
In addition to the diversity of signaling partners, the GPCRs’ status as transmembrane proteins
ensures that local plasma membrane properties perform a central role in the production of
downstream signaling effects. If we set aside differences in the expression profiles of specific
GPCRs, three major mechanisms contribute to shape GPCR signaling; these are the biased
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FIGURE 1 | Schematic representation of the mechanisms shaping the
control of GPCR signaling. The efficacy of a ligand binding to a GPCR is
potentially omnidirectional. Meaning that in theory any physiological outcome
can be produced following the signal transduction event. However, through
various levels of intermolecular and, ultimately, cellular organization the
efficacies of ligands and GPCR function become essentially discrete.
agonism of GPCRs (Violin et al., 2014), secondary messenger
compartmentation (Perera and Nikolaev, 2013) and modulation
by lipid raft association (Escribá et al., 2007). All of these
phenomena will be discussed later in this review (See
Figure 1).
Over the last decades numerous methodological and
technological advances have enabled researchers to better
determine the localized pharmacology of GPCRs from
the perspective of cell membrane structure. However, the
advancement of methods for studying the mechanisms of local
modulation of GPCR signaling to ever greater resolution remains
a necessity. Equally, deeper investigation of the central organizing
principles of this signaling compartmentation at a subcellular
level is required. These advances will allow a better understanding
of the ways in which GPCRs shape cellular physiology. There is
a desire to create drugs based upon improved ligands (Shonberg
et al., 2014) for GPCRs producing very specific (ultra-biased)
mono-directional signaling to reduce off-target effects. This
will only be realized after rigorous assessment of the ways in
which, sub-cellular micro-domains modulate GPCR signaling,
in health and within the context of pathologies. This current is
gaining momentum, particularly within the cardiovascular field;
cardiac muscle has been shown to display examples of highly
defined GPCR signal regulation. In this paper the pharmacology
of multiple GPCRs will be discussed but the adrenoceptors
(ARs) are frequently used as examples, due to them being seen
as a prototypical GPCR by many researchers. This has led to
a large amount of work being focused upon their physiology
and pharmacology. They are also of special interest to the
authors.
The Concept of the Structural GPCR
Microdomain
The effect of a specific ligand on a GPCR is in theory, identical in
all tissues, however, these signaling events often produce different
effects in different cells. For example the binding of an agonist
such as adrenaline to a bAR will increase the contractility of
cardiac muscle but reduce the contractility of airway smooth
muscle (Brodde, 1993; Barnes, 1995). To allow for cell type-
specific divergence, in the downstream effectors of signaling must
be locally organized in space and time (Bethani et al., 2010).
This allows a single stimulus to result in a biologically relevant
whole organ/organism response. The difference mentioned above
is due to the altered targeting of protein kinase A-regulatory type
2 (PKA-RII) by the secondary messenger cAMP within the two
different cell types. In cardiacmuscle PKA phosphorylates L-Type
Ca2+ channels (LTCC) and phospholamban (PLB), the effect of
which is to increase the amplitude and speed of the cellular Ca2+
transient (Brodde, 1993). In smooth muscle cells an increase in
cAMPactivates PKAbutwith the effect that themyosin light chain
kinase (MLCK) is phosphorylated thereby reducing its affinity
for the Ca2+/calmodulin complex and lowering contractility
(Barnes, 1995). Glucagon receptors (GLU-R) activate glycogen
phosphorylase and cause positively inotropic and lusitropic effects
in cardiomyocytes (Farah, 1983). Gs-linked receptors like GLU-R
may cause divergent effects, for example Glucagon-like peptide-
1 receptors (GLP1R) cause negatively inotropic effects (Vila
Petroff et al., 2001). b2AR is also Gs-linked but its effects upon
cardiomyocyte inotropy are somewhat equivocal. Some studies
report it to exert no effect upon relaxation and it cannot activate
glycogen phosphorylase like Glu-R (Xiao and Lakatta, 1993;
Kuznetsov et al., 1995). However, other studies report changes in
inotropy (Bartel et al., 2003).We discovered that b2AR stimulation
affected inotropy to a different degree depending on which region
of the heart the cells were isolated from (Paur et al., 2012).
Equally, we discovered that the cAMP responses of Gs-linked
b1AR and b2AR were quantitatively different at the sub-cellular
level (Nikolaev et al., 2010). In these cases different receptors are
signaling via the same G-protein and the outcome is the same in
terms of signal transduction, i.e., increases in cAMP, but due to
differing cellular organizations the signal is interpreted differently
and the contractile outcome is divergent.
Cyclic Nucleotide Compartmentation
A large and increasing body of work has described biological
mechanisms which serve to shape intracellular cAMP pools
(Mika et al., 2012; Perera and Nikolaev, 2013; Guellich et al.,
2014). This secondary messenger is produced upon the activation
of adenylate cyclase (AC) following the dissociation of the
stimulatory-G (Gs) protein from specific classes of GPCRs.
Compartmentation of cAMP regulatory mechanisms appears to
be a structural phenomenon specific to cell type. This area of
study began to accrete following the pioneering work of Buxton
and Brunton (1983) who asked how it was that two agents
(Prostaglandins and Isoprenaline), which serve to increase cellular
cAMP concentrations via different receptor pathways produce
differing effects upon cellular physiology.
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cAMP produces its effects within cells by causing the activation
of PKA (Zaccolo, 2009), exchange protein activated by cAMP
(Epac; Métrich et al., 2008) or cyclic nucleotide gated channels
(CNGCs; Rochais et al., 2004). Furthermore the cAMP signaling
domains are at once both physical and virtual compartments.
They rely upon the formation of molecular networks which
involve the close apposition of plasma membrane and cellular
organelles such as sarcoplasmic reticulum; in addition, the sub-
cellular localization of phosphodiesterases, phosphatases and
tertiary effectors as well as important protein associations. The
central principle of cAMP compartmentation is that cAMP must
be present in the vicinity of cAMP-dependent effectors (PKA,
Epac, or CNGCs) to cause the transduction of signaling into
physiological changes within the cell (Di Benedetto et al., 2008).
However, it must be prevented from diffusing from the effector
compartment. Therefore cAMP is either degraded or actively
extruded from cells through an energy consuming ATP anion
pump (Wiemer et al., 1982). Stringent control of cAMP levels
assures that a discrete panel of effectors is being activated as a
result of a particular signaling event. The differential activities
of Prostaglandin and Isoprenaline are due to the activation of
different pools of PKAwithin the cardiomyocyte. Due to stringent
control of its localization, cAMP produced as a result of the
activation of Prostaglandin receptors cannot cause the cAMP-
dependent PKA mediated phosphorylation of members of the
excitation-contraction coupling pathway within cardiomyocytes
in the manner of the AR.
Cells organize their effector molecules on the basis of the
specific needs, and as a result the efficacy of a given agonist in a
cell type effectively becomes discrete. Consequently gross changes
in cellular structure or gene expression in response to pathology
which involve this secondary messenger physiology must always
be viewed through this prism. Due to the fact that physiological
effects represent the sum of many stringently controlled local
events it is of great importance to study localized cell signaling.
Membrane Organization
Cyclic AMP compartmentation is heavily controlled by
membrane structures. The following paragraphs will illustrate
the involvement of membranous subcellular domains in the
regulation of signaling compartmentation.
Lipid Rafts
The structure of the lipid bi-layer is essential for maintaining
GPCRs’ defined molecular structure, and therefore, their
function. The lipid make-up of the membrane is not
homogeneous. Indeed, for the past three decades researchers
have been aware of detergent insoluble components of the
lipid bilayer (Simons and Ikonen, 1997). Many fundamental
studies have been carried out to establish the effect of membrane
composition upon GPCR function. Many of these have utilized
rhodopsin due to this molecules status as an archetypal
GPCR for structural studies (Botelho et al., 2002). It appears
that a flexible membrane composed of a greater amount of
lipids with phosphatidylethanolamine (PE) head groups and
docosahexaenoyl chains (DHA), shift rhodopsin toward its
active state. The presence of greater quantities of cholesterol
increases the rigidity of membranes and as a result has been
demonstrated to drive rhodopsin toward its inactive state. The
same study demonstrated this was also true for the depletion
of DHA (Feller and Gawrisch, 2005). The Singer and Nicolson
(1972) fluid mosaic model was postulated and states that the cell
membrane is a fluid bilayer through which protein constituents
are able to float freely. This “lamellar” structure has been
observed to be a basic state of the cell membrane upon which
more complex states are superimposed. The basic state described
above is defined as being liquid crystalline (Yeagle, 2004).
Other states observed are known as gel, pseudo-crystalline,
rippled and liquid ordered (Brown and London, 1997). The
liquid ordered phase is the most interesting of these states
from the perspective of GPCR biology. This configuration is
also frequently described as being a “lipid raft,” as these phases
represent sub-regions of the liquid membrane (Simons and Vaz,
2004). These structures are produced by concentrating the acyl
chains of lipids which were in a gel phase. The result of which
is the preservation of a degree of lateral mobility. Lipid rafts
are enriched in cholesterol and glycosphingolipid and represent
about 30% of cellular membranes. They appear to be intrinsically
important in modulating GPCR function (Oates and Watts,
2011). Scaffolding molecules such as the A-kinase anchoring
proteins (AKAPs), which organize PKA effectors and stabilize
the interaction of phosphodiesterases within their domains, are
also thought to be localized to lipid rafts where they cluster with
the effectors (Kritzer et al., 2012). Caveolae are by far the most
well studied lipid raft domains within the context of GPCR and
cAMP signaling. The role of these domains in controlling GPCR
function is detailed below.
Caveolae
Caveolae are specialized lipid raft domains found in the plasma
membrane of many cell types. They are classed as a distinct
type of lipid raft as they contain specialized scaffolding proteins
such as caveolins and cavins. In two-dimensional transmission
electronmicroscopy (TEM) studies caveolae appear as 50–100 nm
in diameter flask-shaped regions of the lipid bilayer. Thus in
the three dimensional environment of the cell membrane they
are bulb-like invaginations with restricted mouths open to the
extracellular environment (Razani et al., 2002). They appear
to be formed via the concentration of cholesterol and the
aforementioned scaffolding peptides. Caveolae are responsible
for cell signaling, lipid storage and endocytosis. The majority
of cellular studies have historically relied on TEM to visualize
these domains and the cholesterol chelating agent methyl-b-
cyclodextrin (MbCD) to disrupt them (Harvey and Calaghan,
2012). As a pharmacological or physiological tool TEM is limited
in efficacy requiring cells to be fixed and stained although it still
offers the gold standard in spatial resolution. MbCD is extremely
efficacious in removing caveolar domains (as confirmed by TEM
studies) but also results in the non-specific depletion of plasma
membrane cholesterols. Thus non-specific effects may arise and
data obtained from MbCD-based studies should be treated with
some caution. Caveolae also represent mechanosensitive regions
of the cell, in cardiomyocytes they act as reservoirs of membrane
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allowing the cell to increase its surface area in response to osmotic
or mechanical stress. In the case of both stresses caveolae are
observed to disappear in TEM studies (Kohl et al., 2003; Kozera
et al., 2009).
Physiological investigations have revealed that caveolar
depletion results in the loss of compartmentation of cAMP
signaling following b2AR stimulation, thereby altering its effects
on cardiomyocytes function. This appears to be due to the
removal of protein phosphatase (PP) activity suggesting a role
for caveolar localization in controlling the b2AR’s signaling
characteristics (MacDougall et al., 2012; Wright et al., 2014).
Interestingly, b2AR is pleiotropic and may signal via Gs, Gi, or
b-arrestins. Removal of caveolar localization alters this capacity;
caveolar localization appears to be necessary for b2AR to bind Gi
(Xiang et al., 2002). Heart failure has been shown to significantly
alter b2AR-cAMP compartmentation as well as caveolae number
and expression of caveolae scaffolding molecules (Nikolaev et al.,
2010; Feiner et al., 2011). Given the important role of the b2AR as
a cardio-protective molecule this situation may exacerbate heart
failure. The opioid receptor mOR localizes to lipid rafts in various
cell types, including cardiomyocytes where it specifically localizes
in caveolae. Its chronic activation leads to receptor internalization
and can directly influence cAMP levels by “super-activating”
AC. Methyl-b-cyclodextrin disruption of caveolae completely
abolishes this “super-activation” (Zhao et al., 2006). Equally,
transforming growth factor-b (TGF-b) receptors TbRI and
TbRII are assumed to sit inside caveolae. There they regulate the
endothelial nitric oxide synthase (eNOS; Schwartz et al., 2005)
and additional TGF-b signaling downstream effectors which play
a role in various physiological processes such as cell apoptosis
and proliferation (Razani et al., 2001). The activation of TbRI and
TbRII does not change cAMP level; at the same time otherwise
increased cAMP can suppress the TGF-b-dependent signaling
pathways (Schiller et al., 2010). Another receptor assumed to
be situated inside the caveolae is the bradykinin type 2 receptor
(Haasemann et al., 1998; Calizo and Scarlata, 2012). Activation
of this receptor subtype has been shown, at least in vascular
smooth muscle cells, to increase cAMP level (Webb et al., 2010).
In contrast, in adult rat cardiomyocytes bradykinin type receptors
appear to activate their downstream effectors without raising
cAMP level, and this leads to dephosphorylation of the proteins
PLB and troponin I, which reduces cardiomyocyte contractility
(Ke et al., 2010). Though a1 adrenergic receptors (a1AR) appear
to have no effect on cAMP levels (Bogoyevitch et al., 1993), they
can elicit increased contractility and are thought to interact with
the bAR signaling pathway (Brodde and Michel, 1999). Signaling
of the a1AR, i.e., via specialized pools of phosphatidylinositol
(4, 5) bisphosphate (PIP2) is localized to caveolae together with
Gaq and PLCb1 (Morris et al., 2006). It is not clear if the a1AR
themselves are actually inside the caveolae. Instead they might
be localized exclusively at the nuclear membrane. However,
their downstream targets, extracellular signal-regulated kinases
(ERKs) and protein kinase C (PKC) are seen to be located in
caveolae (Petrashevskaya et al., 2004; Wright et al., 2008). It is
generally hypothesized that caveolar localization of receptors
within caveolae leads to their control by compartmentalizing
these molecules with effectors which serve to inhibit their activity
(Head et al., 2005). This control can be exerted by molecules
which act directly upon the receptor, molecules which serve
to produce (Head et al., 2006) cAMP responses or control
downstream effectors of GPCR signaling, such as phosphatases
(MacDougall et al., 2012).
T-tubules
The T-tubules are specialized domains within muscle cell types
which allow efficient transmission of action potentials into the
cell interior. They can be thought of as a further specialization
of the plasma membrane, in a similar fashion to caveolae, as they
represent modified membrane domains with specific scaffolding
proteins (Louch et al., 2010). These include T-cap and Bin-1 as
well as an appreciable amount of caveolin, although the presence
of true caveolae in these structures remains controversial, in
cardiac tissue (Wong et al., 2013). As a result, T-tubules serve as
scaffolds to assemble components of ion channels and receptor
cascades to exert tight control ionic fluxes in response to the
respective extracellular stimuli (Bers, 2002). Certain GPCRs are
found within the T-tubular regions, which appear to exert a
degree of control over their signaling properties. The T-tubules
of cardiomyocytes have been shown to be important organizing
factors for bAR signaling and the disruption of T-tubules during
pathologies alters the physiological outcome of bAR signaling
(Nikolaev et al., 2010). In the adult myocardium the disruption of
the T-tubular system is germane in situations of pathology (Louch
et al., 2010). The general mechanism suggested for t-tubular
control of GPCR signaling is compartmentation with molecular
inhibitors/effectors, much like the situation in caveolae. However,
the large structural aspect of T-tubules, especially those found in
cardiomyocytes means a more physical role is also mooted. In our
study it appeared that the T-tubular domains were able to cause
a tight coupling between membrane domains rich in AKAP and
PKA. The disruption of these domains leads to a b2AR-cAMP
response which was no longer spatially localized. We suggest this
alterationmay lead to an altered panel of effectors for b2ARwithin
diseased cardiomyocytes.
Techniques to Study Localized cAMP
Pharmacology
As the first part of the review has described, overall alterations to
cellular and organ physiology by biochemical stimuli, mediated
by GPCRs, are increasingly understood to be the product of
many structurally defined signaling events where GPCRs, their
secondary messengers and downstream effectors are tightly
regulated at the sub-cellular level. Therefore to understand the
true nature of a given pathway or the intrinsic efficacy of a ligand,
researchers must use techniques with sub-cellular resolution.
Historically, researchers have not been able to determine the
localized pharmacology of GPCRs and instead have relied on
physiological or pharmacological studies of isolated cells or
tissues. Given the current state of knowledge it seems that only by
studying the outcomes at the level of signaling structures/domains
can we move forward in our understanding of these events. We
need to know how the GPCRs, which modify cellular function,
are themselves guided bymicro-domains in specific cell types and
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FIGURE 2 | Schematic representation of the extant modalities for
measuring localized cAMP function within cells. The investigation of
cAMP signaling by patch-clamp electrophysiology, combination scanning ion
conductance microscopy and Förster resonance energy transfer
(SICM/FRET) and FRET microscopy utilizing sensors with subcellular
localization motifs.
how this regulation is altered by pathologies. In cardiac physiology
it remains unclear whether increased aberrant signaling by
GPCRs in pathologies and derangements of T-tubules are an
initiator of, or a response to, abnormal cellular function. The
poor spatial and temporal resolution of traditional biochemical
techniques was what initially led Buxton and Brunton (1983)
to question how it could be that cAMP could cause opposing
biological effects. It has become evident that the localized nature of
GPCR physiology demands localized measurements of secondary
messengers. However, studies of the localized physiology of
signaling events produced by GPCRs in domains of a radius
smaller than 500 nm are rare, as a consequence of the diffraction
limit of light, curtailing the ability of light microscopy methods to
operate at such small scales. In recent years new methods have
emerged which deal with the limitations described above. The
next section will describe the current state of the art in techniques
to study the localized physiology/pharmacology of GPCRs. (See
Figure 2).
Patch Clamp
The patch clamp technique was the first method to effectively
study localized cellular physiology and localized receptor
pharmacology (Auerbach and Sachs, 1984). This technique
exploits the phenomena of ion exchange between the intra and
extracellular regions of impermeable plasma membrane, via
voltage sensitive and ion-selective channels. This technique
has a special utility in the study of electronically excitable cells
such as neurons and muscle cells (myocytes). By placing a
glass micropipette, machined to provide a pore with a radius
of less than a micron onto the surface of a cell and generating
a high resistance seal, the holding voltage of the membrane
can be set. This allows the current and therefore the activity of
ion channels to be recorded. A number of studies have used a
modified patch clamp technique to indirectly investigate GPCR
dependent cAMP production (Rochais et al., 2004; Abi-Gerges
et al., 2009; Ghigo et al., 2012). The focus of many of these studies
was the adenylyl cyclase family. Most utilized the properties of
certain Ca2+-transporting channels which are modulated by
cyclic nucleotides (CNGCs) and which co-localize with adenylyl
cyclases in cell membranes (Finn et al., 1996). Although the
wild-type channels do not differentiate very effectively between
cAMP and cGMP, mutations causing increased selectivity have
been produced. Site-directed mutagenesis has been used to alter
a single glutamic acid residue to a methionine (E583M) and
a further compound mutation of a cysteine to a tryptophan
(C460W/E583M) (Rochais et al., 2004). This produced two
separate cAMP sensing channels; these have been expressed
in various primary cell types (Rich et al., 2001). Consecutive
patching reveals channels which give responses on the basis of
local cAMP levels. The modulation of CNGCs current as a result
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of the application of receptor agonists or external stimuli can be
obtained by standard electrophysiological means. Further work
looked at the hyperpolarizing cation channels (HCN) which are
between 10 and 1000 times more sensitive to cAMP than CNGCs
(Rich et al., 2001). These channels are related in that they both
contain an evolutionarily conserved cyclic nucleotide binding
cassette domain (CNBD). Their development built upon the work
of Trivedi and Kramer (1998) who pioneered what was the first
method to give truly localized real-time measurement of GPCR
activity, “patch-cramming.” The patch-cramming technique is
based upon the activity cyclic nucleotide sensitive ion channels
and involves excision of patches from the lipid membrane
bi-layer of cell types which express a high density of CNGCs, for
example of oocytes or retinal rod cells, with a patch clamp pipette.
Through this operation an inside-out patch of cell membrane will
be removed and the CNGCs within can be used to sense external
cAMP levels. Calibration of these isolated channels is possible
with external solutions containing predefined concentrations
of cyclic nucleotides. The CNGC based pipette sensor can then
be “crammed” into a cell of interest for which the level of the
secondary messenger is to be determined.
Localized Förster Resonance Energy Transfer
(FRET) Sensors
A further way to study the localized pharmacology of GPCRs
would be to use FRET sensors which are localized to a sub-
cellular region of interest. The general approach of this technique
is to produce genetically encoded peptide constructs comprising
a targeting motif, a signaling molecule binding region and a
fluorescent sensor component. The sensor component is usually
two fluorophores which are designed, so as to be held in a
specific conformation upon the folding of the peptide. One
fluorophore acts as an energy donor and the other is an energy
acceptor. These fluorophores are either brought into or moved
out of proximity upon the binding of the messenger molecule of
interest, the result is an alteration in the fluorescence of the donor
fluorophore due to the phenomenon of Förster resonance energy
transfer. These alterations can be measured by either ratiometric
or fluorescence life-time protocols to give an indication of the
relative concentration of the secondary messenger molecule of
interest in the proximity of the sensor (Sprenger and Nikolaev,
2013). The location targeting motif ensures that the measurement
of FRET responses after secondary, messenger activity occurs
within a specific locality.
FRET-based investigation of secondary messenger activity is a
somewhat immature field, but localized FRET sensor technology
has been a critical component of this field since its inception.
The seminal studies of Zaccolo and collaborators describe the
production of sensors based upon the regulatory I and II (RI/RII)
regions of PKA (Zaccolo and Pozzan, 2002). This resulted in
sensors which were localized to either the PKA_RI or RII
regions. These are regions which, within the cardiomyocytes,
control different aspects of cellular physiology. Thereby it was
made possible to demonstrate that cAMP pools activated upon
Isoprenaline (bAR) or Prostacyclin (EPR) were indeed discrete
(Di Benedetto et al., 2008). Interestingly, non-localized sensors
were developed later than localized sensors as a solution to
the problem of the high sensitivity of PKA-based constructs.
As cAMP is often present at high concentrations within cells
the initial class of FRET sensors were easily saturated, meaning
experiments lost resolution at physiological levels of cAMP
production. Non-localized sensors have most often been based
upon the cAMP binding domains of EPAC1 or EPAC2 (Nikolaev
et al., 2004). These sensors have shown efficacy in studies
assessing the diffusion of cAMP throughout the cell (Nikolaev
et al., 2006). Transgenic technology has allowed the HCN2 and
Epac1 sensors to be incorporated into mouse DNA, creating
strains of animal which express these sensors within every cell
of their body (Nikolaev et al., 2006; Calebiro et al., 2009). cGMP
sensors have been created by using the cAMP binding domains
of phosphodiesterases or PKG as their detector region. There
is a transgenic mouse strain with the RED DE5 cAMP sensor
(Sprenger et al., 2015).
On the basis of these general sensors with lower sensitivity,
localized sensors have been created by fusing various localization
domains. Many if not all of the applications of these localized
sensors have been focused upon investigating the molecular
actors involved in modulating excitation-contraction coupling
within the cardiomyocyte. This is the result of a relatively small
number of groups being involved in this process and their general
interest in the cardiac field. Fusions of the PKA-RI and RII
regulatory domains with the non-localized Epac-1 sensor were
introduced as an update of the original genetically encoded
FRET sensors by the Zaccolo group and measure cAMP in PKA
microdomains (Di Benedetto et al., 2008). Fusions of cGMP and
cAMP sensing domains have been made with the N-termini
of phosphodiesterases to investigate the dynamics of secondary
messengers within the vicinity of the molecules charged with
controlling their levels (Herget et al., 2008). Fascinating studies
have been conducted looking at specificmembranemicrodomains
such as the sarcoplasmic reticulum, which are beyond the reach
of the pipette based approaches discussed in this review. These
have investigated cAMP levels and the activity of PKA in these
regions (Dyachok et al., 2006; Liu et al., 2011). Equally, the plasma
membrane itself has been investigated with a fusion peptide
targeted toward caveolar membranes by fusion with a motif from
Lyn kinase (Wachten et al., 2010; Mohamed et al., 2011). As well
as this the domains of specific adenyl cyclases have been probed
by fusions of Epac2 and AC8. The membranes of mitochondria
and the nucleus have been probed by fusion of mitochondrial
sequences and nuclear targeting motifs to the ICUE (indicator of
cAMP using Epac) class of FRET sensors (DiPilato et al., 2004;
Sample et al., 2012). This area and other biophysical techniques for
cyclic nucleotide measurement have been reviewed in exhaustive
detail by Sprenger and Nikolaev (2013).
Scanning Ion Conductance Microscopy/FRET
(SICM/FRET)
Scanning ion conductance microscopy (SICM) was developed
by Paul Hansma who realized that ion fluxes, present when
performing patch clamp experiments, could also be used to image
cellular topography (Hansma et al., 1989). The glass capillary
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pipettes of a type similar to that is utilized in patch clamping, but
of higher resistance, are able to function as a scanning probe. The
ion flux present between the negative electrode inside the pipette
and the positive one in the bath is reduced when the pipette tip
is moved in close proximity to cellular structures. This results
in a drop in conductance and a measurable drop in current. By
scanning the pipette across the surface of interest a 3D map of the
relative variance in conductance can be built up. The system is
run in a feedback mode meaning that conductance may not drop
beneath a pre-defined value; this prevents the pipette from coming
into contact with the sample surface. The topographical images
acquired by this imaging modality give sub-optical resolution,
which is defined and only limited by the radius of the pipette
tip. SICM scans bear a striking resemblance to scanning electron
micrograph images only cells and other biological objects are live
and non-prepared, unlike the aforementioned imaging modality
(Miragoli et al., 2011). Novak et al pioneered the “Hopping
Mode” approach which removed image artifacts caused by large
structures obstructing the scanning pipette in the x/y directions
(Novak et al., 2009).
Clearly the pipette itself cannot monitor GPCRs function; this
imaging modality must be multiplexed with other techniques.
In our group SICM has been used in combination with FRET
microscopy to study GPCR function. SICM is able to resolve
complex membrane topography and the nanopipette allows
application of picolitres of solution to cells. FRETmicroscopy can
then offer a “read-out” upon the relative presence of a secondary
messenger response (Nikolaev et al., 2010; Wright et al., 2014).
The resolution of SICM utilized in the two studies using this
hybrid technique has been around 200 nm, allowing T-tubule
openings to be observed in adult cardiomyocytes. This means that
the openings of individual T-tubular regions can be targeted for
agonist application. The presence of cAMP responses can then
be investigated at points both near and far from the region of
application to assess the relative diffusion/ propagation of the
cAMP response upon agonist application. The measurement of
the propagation of cAMP within the cell cytosol is only possible
with a non-localized FRET sensor. This makes this class of sensor
important for thismodality. In one of the extant studies amodified
high-resolution SICM setup was able to resolve structures on
the scale of 50 nm which may be caveolae, meaning that these
structures could be targeted at some point in the future.
In normal cardiomyocytes transfected with a cAMP-sensing
FRET construct SICM/FRET has demonstrated that b2AR are
strictly localized to T-tubules (Nikolaev et al., 2010). Application
of Isoprenaline from the nanopipette into T-tubules, but not to the
areas between T-tubules (cellular sarcolemma crests) gives rise to
stringently localized sub-cellular cAMP responses. This situation
is subverted in failing cardiomyocytes, T-tubules are disrupted
and the application of Isoprenaline to cellular crests begins to
elicit b2AR-cAMP responses. The cyclic AMP response following
b2AR stimulation also loses its stringent localization in space.
The pathological consequences of this alteration are not clear,
but it may contribute to the loss of contractile function observed
in the failing myocardium and the apparent desensitization of
the myocardium to sympathetic input. If this is the case then
it is clear that a disruption of the sub-cellular environment in
the setting of pathology, even if not modifying the intrinsic
properties of receptors, can modify its extrinsic pharmacological
function. A follow up study assessed the treatment of rats with an
experimental gene therapy technique (Lyon et al., 2012), which
caused the overexpression of the Ca2+ pump SERCA2a in failing
cardiomyocytes. This treatment restored the T-tubular structure
of the failing cardiomyocytes and the b2AR responsewas observed
in the T-tubule whilst a response which was inducible at the
crest was no longer present. This demonstrated the importance of
maintaining discrete sub-cellular structures to enable the proper
control of cAMP compartmentation.
In parallel to the disruption of T-tubular structures the
caveolar domains also appeared to heavily modify b2AR-cAMP
compartmentation (Wright et al., 2014). MbCD caused the b2AR-
cAMP response to appear upon cellular sarcolemmal crests
and to propagate throughout the cell. Further to that, the
importance of cAMP compartmentation by caveolar structures
was exposed by knocking down Caveolin-3 (cav-3) (Wright et al.,
2014). This displacement caused the b2AR-cAMP response to
remain localized to T-tubular domains but caused the cAMP
response to propagate throughout the cell. Over-expression of
cav-3 in failing cardiomyocytes was able to restore localized
b2AR-cAMP response which was previously deranged. A novel
computer model has been produced which accurately predicted
the displacement of cav-3 to be more difficult at the sarcolemma
in relation to the crest due to the differences in the formation
of caveolae in the different regions of the cardiomyocytes
(Wright et al., 2014). The latter prediction was confirmed
by an entirely separate work using super-resolution confocal
microscopy techniques (Wong et al., 2013).
Conclusion
As this review demonstrates the function of GPCRs and the
control of cAMP and other secondary messengers cannot be
divorced from the membrane environment that these molecules
are localized within. As a result only through understanding
how these domains affect the function of GPCRs and control
cAMP responses can one begin to understand how to rationally
manipulate intracellular cAMP responses to provide benefit
within the contexts of human pathology. The studies reviewed
have exclusively been performed in animal models and many, as
discussed, have been performed by groups with a special interest
in the cardiac field. The cardiomyocyte is a singular cell type and
presents a degree of structural complexity second perhaps only to
that of neurons. As a result the apparent stringency of secondary
messenger compartmentation by structural means may not be as
essential in other cell types.
The techniques above present avenues toward the assessment
of GPCR function at the level of membrane localization.
The techniques are not prohibitively sophisticated, with SICM
being, at least in theory, within reach of laboratories utilizing
patch-clamp technology. Equally, simple ratiometric FRET is a
straightforward microscopy technique and the combination of
SICM/FRET requires only the co-ordination of both techniques.
Adenoviral and plasmid constructs encoding various localized
and general FRET sensors targeted at different secondmessengers
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are becoming widely available to the research community. The
emergence of a greater number of manufacturers on the market
for this instrumentation will drive more researchers to adopt what
has proven to be very powerful experimental approaches.
Acknowledgments
This work was supported by the Welcome Trust (JG-WT090594)
and the British Heart Foundation (JG-12/18/30088).
References
Abi-Gerges, A., Richter, W., Lefebvre, F., Mateo, P., Varin, A., Heymes, C., et
al. (2009). Decreased expression and activity of cAMP phosphodiesterases in
cardiac hypertrophy and its impact on b-adrenergic cAMP signals.Circ. Res. 105,
784–792. doi: 10.1161/CIRCRESAHA.109.197947
Auerbach, A., and Sachs, F. (1984). Patch clamp studies of single
ionic channels. Ann. Rev. Biophys. Bioeng. 13, 269–302. doi:
10.1146/annurev.bb.13.060184.001413
Barnes, P. J. (1995). Beta-adrenergic receptors and their regulation. Am. J. Resp.
Crit. Care Med. 152, 838–860. doi: 10.1164/ajrccm.152.3.7663795
Bartel, S., Krause, E.-G., Wallukat, G., and Karczewski, P. (2003). New insights into
b2-adrenoceptor signaling in the adult rat heart. Cardiovasc. Res. 57, 694–703.
doi: 10.1016/S0008-6363(02)00720-4
Bers, D. M. (2002). Cardiac excitation-contraction coupling. Nature 415, 198–205.
doi: 10.1038/415198a
Bethani, I., Skånland, S. S., Dikic, I., and Acker-Palmer, A. (2010). Spatial
organization of transmembrane receptor signaling. EMBO J. 29, 2677–2688. doi:
10.1038/emboj.2010.175
Bogoyevitch, M. A., Fuller, S. J., and Sugden, P. H. (1993). cAMP and protein
synthesis in isolated adult rat heart preparations. Am. J. Physiol. 265,
C1247–C1257.
Botelho, A. V., Gibson, N. J., Thurmond, R. L., Wang, Y., and Brown, M. F. (2002).
Conformational energetics of rhodopsin modulated by nonlamellar-forming
lipids. Biochemistry 41, 6354–6368. doi: 10.1021/bi011995g
Brodde, O. (1993). Beta-adrenoceptors in cardiac disease. Pharmacol. Ther. 60,
405–430. doi: 10.1016/0163-7258(93)90030-H
Brodde, O., and Michel, M. C. (1999). Adrenergic and muscarinic receptors in the
human heart. Pharmacol. Rev. 51, 651–690.
Brown, D. A., and London, E. (1997). Structure of Detergent-resistant membrane
domains: does phase separation occur in biological membranes? Biochem.
Biophys. Res. Comms. 240, 1–7. doi: 10.1006/bbrc.1997.7575
Buxton, I. L., and Brunton, L. L. (1983). Compartments of cyclic amp and protein
kinase in mammalian cardiomyocytes. J. Biol. Chem. 258, 10233–10239.
Calebiro, D., Nikolaev, V. O., Gagliani, M. C., de Filippis, T., Dees,
C., Tacchetti, C., et al. (2009). Persistent cAMP-signals triggered by
internalized G-Protein–coupled receptors. PLoS Biol. 7:e1000172. doi:
10.1371/journal.pbio.1000172
Calizo, R. C., and Scarlata, S. (2012). A role for G-Proteins in directing G-
Protein-coupled receptor–caveolae localization. Biochemistry 51, 9513–9523.
doi: 10.1021/bi301107p
Conti, M., and Beavo, J. (2007). Biochemistry and physiology of cyclic nucleotide
phosphodiesterases: essential components in cyclic nucleotide signaling. Annu.
Rev. Biochem. 76, 481–511.
Di Benedetto, G., Zoccarato, A., Lissandron, V., Terrin, A., Li, X., Houslay,
M. D., et al. (2008). Protein kinase A type I and type II define distinct
intracellular signaling compartments. Circ. Res. 103, 836–844. doi:
10.1161/CIRCRESAHA.108.174813
DiPilato, L.M., Cheng, X., andZhang, J. (2004). Fluorescent indicators of cAMP and
epac activation reveal differential dynamics of cAMP signaling within discrete
subcellular compartments. Proc. Natl. Acad. Sci. U.S.A. 101, 16513–1618. doi:
10.1073/pnas.0405973101
Dyachok, O., Isakov, Y., Sagetorp, J., and Tengholm, A. (2006). Oscillations of cyclic
AMP in hormone-stimulated insulin-secreting b-Cells. Nature 439, 349–352.
doi: 10.1038/nature04410
Escribá, P. V., Wedegaertner, P. B., Goñi, F. M., and Vögler, O. (2007). Lipid-
protein interactions in GPCR-associated signaling. Biochim. Biophysic. Acta
1768, 836–852. doi: 10.1016/j.bbamem.2006.09.001
Farah, A. E. (1983). Glucagon and the circulation. Pharmacol. Rev. 35, 181–217.
Feiner, E. C., Chung, P., Jasmin, J. M., Zhang, J., Whitaker-Menezes, D., Myers,
V., et al. (2011). Left ventricular dysfunction in murine models of heart failure
and in failing human heart is associated with a selective decrease in the
expression of caveolin-3. J. Card. Fail. 17, 253–263. doi: 10.1016/j.cardfail.2010.
10.008
Feller, S. E., and Gawrisch, K. (2005). Properties of docosahexaenoic-acid-
containing lipids and their influence on the function of rhodopsin. Curr. Opin.
Struct. Biol. 15, 416–422. doi: 10.1016/j.sbi.2005.07.002
Finn, J. T., Grunwald, M. E., and Yau, K. W. (1996). Cyclic nucleotide-gated ion
channels: an extended family with diverse functions. Ann. Rev. Physiol. 58,
395–426. doi: 10.1146/annurev.ph.58.030196.002143
Ghigo, A., Perino, A., Mehel, H., Zahradníková, A., Morello, F., Leroy, J., et
al. (2012). Phosphoinositide 3-kinase g protects against catecholamine-
induced ventricular arrhythmia through protein kinase a–mediated
regulation of distinct phosphodiesterases. Circulation 126, 2073–2083.
doi: 10.1161/CIRCULATIONAHA.112.114074
Guellich, A., Mehel, H., and Fischmeister, R. (2014). Cyclic AMP synthesis and
hydrolysis in the normal and failing heart. Pflügers Arch. 466, 1163–1175. doi:
10.1007/s00424-014-1515-1
Haasemann, M., Cartaud, J., Muller-Esterl, W., and Dunia, I. (1998). Agonist-
Induced Redistribution of Bradykinin B2 Receptor in Caveolae. J. Cell Sci. 111,
917–28.
Hansma, P. K., Drake, B., Marti, O., Gould, S. A., and Prater, C. B. (1989).
The scanning ion-conductance microscope. Science 243, 641–643. doi:
10.1126/science.2464851
Harvey, R. D., and Calaghan, S. C. (2012). Caveolae create local signaling domains
through their distinct protein content, lipid profile andmorphology. J. Mol. Cell.
Cardiol. 52, 366–375. doi: 10.1016/j.yjmcc.2011.07.007
Head, B. P., Patel, H. H., Roth, D. M., Lai, N. C., Niesman, I. R., Farquhar,
M. G., et al. (2005). G-protein-coupled receptor signaling components
localize in both sarcolemmal and intracellular caveolin-3-associated
microdomains in adult cardiac myocytes. J. Biol. Chem. 280, 31036–31044. doi:
10.1074/jbc.M502540200
Head, B. P., Patel, H. H., Roth, D. M., Murray, F., Swaney, J. S., Niesman, I. R.,
et al. (2006). Microtubules and actin microfilaments regulate lipid raft/caveolae
localization of adenylyl cyclase signaling components. J. Biol. Chem. 281,
26391–26399. doi: 10.1074/jbc.M602577200
Herget, S., Lohse, M. J., and Nikolaev, V. O. (2008). Real-time monitoring of
phosphodiesterase inhibition in intact cells. Cell. Signal. 20, 1423–1431. doi:
10.1016/j.cellsig.2008.03.011
Kenakin, T. (2011). Functional selectivity and biased receptor signaling. J.
Pharmacol. Exp. Ther. 336, 296–302. doi: 10.1124/jpet.110.173948
Ke, Y., Sheehan, K., Egom, E. E., Lei, M., and Solaro, R. J. (2010). Novel
bradykinin signaling in adult rat cardiac myocytes through activation of p21-
activated kinase. Am. J. Physiol. Heart Circ. Physiol. 298, H1283–H1289. doi:
10.1152/ajpheart.01070.2009
Kohl, P., Cooper, P. J., and Holloway, H. (2003). Effects of acute ventricular volume
manipulation on in situ cardiomyocyte cell membrane configuration. Prog.
Biophys. Mol. Biol. 82, 221–227. doi: 10.1016/S0079-6107(03)00024-5
Kozera, L., White, E., and Calaghan, S. (2009). Caveolae act as membrane reserves
which limit mechanosensitive ICl;swell channel activation during swelling in the
rat ventricular myocyte. PLoS ONE 4:e8312. doi: 10.1371/journal.pone.0008312
Kritzer, M. D., Li, J., Dodge-Kafka, K., and Kapiloff, M. S. (2012). AKAPs: the
architectural underpinnings of local cAMP signaling. J. Mol. Cell. Cardiol. 52,
351–358. doi: 10.1016/j.yjmcc.2011.05.002
Kuznetsov, V., Pak, E., Robinson, R. B., and Steinberg, S. F., (1995). b2-adrenergic
receptor actions in neonatal and adult rat ventricular myocytes. Circ. Res. 76,
40–52.
Liu, S., Zhang, J., and Xiang, Y. K. (2011). FRET-based direct detection of dynamic
protein kinase a activity on the sarcoplasmic reticulum in cardiomyocytes.
Biochem. Biophys. Res. Comms. 404, 581–586. doi: 10.1016/j.bbrc.2010.11.116
Louch, W. E., Sejersted, O. M., and Swift, F. (2010). There goes the neighborhood:
pathological Alterations in T-tubule morphology and consequences for
cardiomyocyte Ca2+ Handling. J. Biomed. Biotech. 2010, 503906. doi:
10.1155/2010/503906.
Frontiers in Pharmacology | www.frontiersin.org July 2015 | Volume 6 | Article 1488
Wright et al. GPCR/cAMP pharmacology from the perspective of structure
Lyon, A. R., Nikolaev, V. O., Miragoli, M., Sikkel, M. B., Paur, H., Benard,
L., et al. (2012). Plasticity of surface structures and b2-adrenergic receptor
localization in failing ventricular cardiomyocytes during recovery from heart
failure. Circ. Heart Fail. 5, 357–365. doi: 10.1161/CIRCHEARTFAILURE.111.
964692
MacDougall, D. A., Agarwal, S. R., Stopford, E. A., Chu, H., Collins, J. A.,
Longster, A. L., et al. (2012). Caveolae compartmentalise b2-adrenoceptor
signals by curtailing camp production and maintaining phosphatase activity in
the sarcoplasmic reticulumof the adult ventricularmyocyte. J.Mol. Cell. Cardiol.
52, 388–400. doi: 10.1016/j.yjmcc.2011.06.014
Métrich,M., Lucas, A., Gastineau,M., Samuel, J., Heymes, C.,Morel, E., et al. (2008).
Epac mediates b-adrenergic receptor–induced cardiomyocyte hypertrophy.
Circ. Res. 102, 959–965. doi: 10.1161/CIRCRESAHA.107.164947
Mika, D., Leroy, J., Vandecasteele, G., and Fischmeister, R. (2012). PDEs create
local domains of cAMP signaling. J. Mol. Cell. Cardiol. 52, 323–329. doi:
10.1016/j.yjmcc.2011.08.016
Miragoli, M., Moshkov, A., Novak, P., Shevchuk, A., Nikolaev, V. O., El-Hamamsy,
I., et al. (2011). Scanning ion conductance microscopy: a convergent high-
resolution technology for multi-parametric analysis of living cardiovascular
cells. J. Royal Soc. Int. 8, 913–925. doi: 10.1098/rsif.2010.0597
Mohamed, T. M. A., Oceandy, D., Zi, M., Prehar, S., Alatwi, N., Wang, Y.,
et al. (2011). Plasma membrane calcium pump (PMCA4)-neuronal nitric-
oxide synthase complex regulates cardiac contractility through modulation
of a compartmentalized cyclic nucleotide microdomain. J. Biol. Chem. 286,
41520–41529. doi: 10.1074/jbc.M111.290411
Morris, J. B., Huynh, H., Vasilevski, O., andWoodcock, E. A. (2006). a1-adrenergic
receptor signaling is localized to caveolae in neonatal rat cardiomyocytes. J. Mol.
Cell. Cardiol. 41, 17–25. doi: 10.1016/j.yjmcc.2006.03.011
Neves, S. R., Ram, P. T., and Iyengar, R. (2002). G protein pathways. Science 296,
1636–1639. doi: 10.1126/science.1071550
Nikolaev, V. O., Bünemann, M., Hein, L., Hannawacker, A., and Lohse, M. J. (2004).
Novel single chain cAMP sensors for receptor-induced signal propagation. J.
Biol. Chem. 279, 37215–37218. doi: 10.1074/jbc.C400302200
Nikolaev, V. O., Bünemann, M., Schmitteckert, E., Lohse, M. J., and Engelhardt,
S. (2006). Cyclic AMP imaging in adult cardiac myocytes reveals far-
reaching b1-adrenergic but locally confined b2-adrenergic receptor–mediated
signaling. Circ. Res. 99, 1084–1091. doi: 10.1161/01.RES.0000250046.
69918.d5
Nikolaev, V. O., Moshkov, A., Lyon, A. R., Miragoli, M., Novak, P., Paur, H.,
et al. (2010). b2-adrenergic receptor redistribution in heart failure changes
cAMP compartmentation. Science 327, 1653–1657. doi: 10.1126/science.
1185988
Novak, P., Li, C., Shevchuk, A. I., Stepanyan, R., Caldwell, M., Hughes, S., et
al. (2009). Nanoscale live-cell imaging using hopping probe ion conductance
microscopy. Nat. Meth. 6, 279–281. doi: 10.1038/nmeth.1306
Oates, J., andWatts, A. (2011). Uncovering the intimate relationship between lipids,
cholesterol and GPCR activation. Curr. Opin. Struct. Biol. 21, 802–807. doi:
10.1016/j.sbi.2011.09.007
Paur, H., Wright, P. T., Sikkel, M. B., Tranter, M. H., Mansfield, C., O’Gara,
P., et al. (2012). High levels of circulating epinephrine trigger apical
cardiodepression in a b2-adrenergic receptor/gi-dependent manner a
new model of takotsubo cardiomyopathy. Circulation 126, 697–706. doi:
10.1161/CIRCULATIONAHA.112.111591
Perera, R. K., and Nikolaev, V. O. (2013). Compartmentation of cAMP signaling
in cardiomyocytes in health and disease. Acta Physiol. 207, 650–662. doi:
10.1111/apha.12077
Petrashevskaya, N. N., Bodi, I., Koch, S. E., Akhter, S. A., and Schwartz, A.
(2004). Effects of a1-adrenergic stimulation on normal and hypertrophied
mouse hearts. relation to caveolin-3 expression.Cardiovasc. Res. 63, 561–72. doi:
10.1016/j.cardiores.2004.01.026
Razani, B., Woodman, S. E., and Lisanti, M. P. (2002). Caveolae: from cell
biology to animal physiology. Pharmacol. Rev. 54, 431–467. doi: 10.1124/pr.54.
3.431
Razani, B., Zhang, X. L., Bitzer, M., Gersdorff, G., and Böttinger, E. P., and Lisanti,
M. P. (2001). Caveolin-1 regulates TransformingGrowth Factor (TGF)-b/SMAD
signaling through an interaction with the TGF-(b type I receptor. J. Biol. Chem.
276, 6727–6738. doi: 10.1074/jbc.M008340200
Rich, T. C., Tse, T. E., Rohan, J. G., Schaack, J., and Karpen, J. W. (2001).
In vivo assessment of local phosphodiesterase activity using tailored cyclic
nucleotide–gated channels as cAMP sensors. J. Gen. Physiol. 118, 63–78. doi:
10.1085/jgp.118.1.63
Rochais, F., Vandecasteele, G., Lefebvre, F., Lugnier, C., Lum, H., Mazet, J., et
al. (2004). Negative feedback exerted by cAMP-dependent protein kinase and
cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac
myocytes: an in vivo study using adenovirus-mediated expression of CNG
channels. J. Biol. Chem. 279, 52095–52105. doi: 10.1074/jbc.M405697200
Sample, V., DiPilato, L. M., Yang, J. H., Ni, Q., Saucerman, J. J., and Zhang, J. (2012).
Regulation of nuclear PKA revealed by spatiotemporal manipulation of cAMP.
Nat. Chem. Biol. 8, 375–382. doi: 10.1038/nchembio.799
Schiller, M., Dennler, S., Anderegg, U., Kokot, A., Simon, J. C., Luger T. A., et al.
(2010). Transforming growth factor-b/Smad-induced expression of extracellular
matrix components and other key fibroblast effector functions. J. Biol. Chem.
285, 409–421. doi: 10.1074/jbc.M109.038620
Schwartz, E. A., Reaven, E., Topper, J. N., and Tsao, P. S. (2005). Transforming
growth factor-b receptors localize to caveolae and regulate endothelial nitric
oxide synthase in normal human endothelial cells. Biochem. J. 390, 199–206. doi:
10.1042/BJ20041182
Shonberg, J., Lopez, L., Scammells, P. J., Christopoulos, A., Capuano, B., and Lane, J.
R. (2014). Biased agonism at G protein-coupled receptors: the promise and the
challenges—a medicinal chemistry perspective. Med. Res. Rev. 34, 1286–1330.
doi: 10.1002/med.21318
Shukla, A. K., Xiao, K., and Lefkowitz, R. J. (2011). Emerging paradigms of b-
arrestin-dependent seven transmembrane receptor signaling. Trends Biochem.
Sci. 36, 457–469. doi: 10.1016/j.tibs.2011.06.003
Simons, K., and Ikonen, E. (1997). Functional rafts in cell membranes. Nature 387,
569–572. doi: 10.1038/42408
Simons, K., and Vaz, W. L. C. (2004). Model systems, lipid rafts, and
cell membranes 1. Annu. Rev. Biophys. Biomol. Struct. 33, 269–295. doi:
10.1146/annurev.biophys.32.110601.141803
Singer, S. J., and Nicolson, G. L. (1972). The fluid mosaic model of the structure of
cell membranes. Science 175, 720–731. doi: 10.1126/science.175.4023.720
Sprenger, J. U., and Nikolaev, V. O. (2013). Biophysical techniques for detection
of cAMP and cGMP in living cells. Int. J. Mol. Sci. 14, 8025–8046. doi:
10.3390/ijms14048025
Sprenger, J. U., Perera, R. K., Steinbrecher, J. H., Lehnart, S. E., Maier, L. S.,
Hasenfuss G., et al. (2015). In vivo model with targeted cAMP biosensor
reveals changes in receptor-microdomain communication in cardiac disease.
Nat. Commun. 6, 6965. doi: 10.1038/ncomms7965
Trivedi, B., and Kramer, R. H. (1998). Real-time patch-cram detection of
intracellular cGMP reveals long-term suppression of responses to NO
and muscarinic agonists. Neuron 21, 895–906. doi: 10.1016/S0896-6273(00)
80604-2
Vila Petroff, M. G., Egan, J. M., Wang, X., and Sollott, S. J. (2001). Glucagon-like
peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac
myocytes. Circ. Res. 89, 445–452. doi: 10.1161/hh1701.095716
Violin, J. D., Crombie, A. L., Soergel, D. G., and Lark, M. W. (2014). Biased ligands
at G-protein-coupled receptors: promise and progress. Trends Pharmacol. Sci.
35, 308–316. doi: 10.1016/j.tips.2014.04.007
Wachten, S., Masada, N., Ayling, L., Ciruela, A., Nikolaev, V. O., Lohse, M. J., et al.
(2010). Distinct pools of cAMP centre on different isoforms of adenylyl cyclase
in pituitary-derived GH3B6 cells. J. Cell Sci. 123, 95–106. doi: 10.1242/jcs.
058594
Wiemer, G., Hellwich, U., Wellstein, A., Dietz, J., Hellwich, M., and Palm,
D. (1982). Energy-dependent extrusion of cyclic 30,50-adenosine-
monophosphate. Naunyn. Schmiedebergs Arch. Pharmacol. 321, 239–246.
doi: 10.1007/BF00498507
Webb, J. G., Tan, Y., Jaffa, M. A., and Jaffa, A. A. (2010). Evidence for prostacyclin
and cAMP upregulation by bradykinin and insulin-like growth factor 1 in
vascular smooth muscle cells. J. Recept. Signal Transduct. Res. 30, 61–71. doi:
10.3109/10799890903563768
Wong, J., Baddeley, D., Bushong, E. A., Yu, Z., Ellisman, M. H., Hoshijima, M.,
et al. (2013). Nanoscale distribution of ryanodine receptors and caveolin-3 in
mouse ventricularmyocytes: dilation of T-tubules near junctions.Biophys. J. 104,
L22–L24. doi: 10.1016/j.bpj.2013.02.059
Wright, C. D., Chen, Q., Baye, N. L., Huang, Y., Healy, C. L., Kasinathan,
S., et al. (2008). Nuclear a1-adrenergic receptors signal activated ERK
localization to caveolae in adult cardiac myocytes. Circ. Res. 103, 992–1000. doi:
10.1161/CIRCRESAHA.108.176024
Frontiers in Pharmacology | www.frontiersin.org July 2015 | Volume 6 | Article 1489
Wright et al. GPCR/cAMP pharmacology from the perspective of structure
Wright, P. T., Nikolaev, V. O., O’Hara, T., Diakonov, I., Bhargava, A., Tokar,
S., et al. (2014). Caveolin-3 regulates compartmentation of cardiomyocyte b2-
adrenergic receptor-mediated cAMP signaling. J. Mol. Cell. Cardiol. 67, 38–48.
doi: 10.1016/j.yjmcc.2013.12.003
Xiang, Y., Rybin, V. O., Steinberg, S. F., and Kobilka, B. (2002). Caveolar localization
dictates physiologic signaling of b2-adrenoceptors in neonatal cardiacmyocytes.
J. Biol. Chem. 277, 34280–34286. doi: 10.1074/jbc.M201644200
Xiao, R. P., and Lakatta, E. G. (1993). Beta 1-adrenoceptor stimulation and beta 2-
adrenoceptor stimulation differ in their effects on contraction, cytosolic Ca2+,
and Ca2+ current in single rat ventricular cells. Circ. Res. 73, 286–300.
Yeagle, P. L. (2004). The Structure of Biological Membranes. Boca Raton, FL: CRC
press, 250–251.
Zaccolo, M. (2009). cAMP signal transduction in the heart: understanding spatial
control for the development of novel therapeutic strategies. Brit. J. Pharmacol.
158, 50–60. doi: 10.1111/j.1476-5381.2009.00185.x
Zaccolo, M., andMovsesian, M. (2007). cAMP and cGMP signaling cross-talk: role
of phosphodiesterases and implications for cardiac pathophysiology. Circ. Res.
100, 1569–1578. doi: 10.1161/CIRCRESAHA.106.144501
Zaccolo,M., and Pozzan, T. (2002). Discretemicrodomains with high concentration
of cAMP in stimulated rat neonatal cardiac myocytes. Science 295, 1711–1715.
doi: 10.1126/science.1069982
Zhao, H., Loh, H. H., and Law, P. Y. (2006). Adenylyl cyclase superactivation
induced by long-term treatment with opioid agonist is dependent on receptor
localized within lipid rafts and is independent of receptor internalization. Mol.
Pharmacol. 69, 1421–1432. doi: 10.1124/mol.105.020024
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Wright, Schobesberger and Gorelik. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org July 2015 | Volume 6 | Article 14810
